Upregulation of endoglin (CD105) expression during childhood brain tumor-related angiogenesis. Anti-angiogenic therapy

Anticancer Research

Volumn 18, Issue 3 A, 1998, Pages 1485-1500

  Bodey, Bela ^a,e   Bodey Jr , Bela ^a   Siegel, Stuart E ^b   Kaiser, Hans E ^c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF VIENNA   (Austria)

^e NONE   (United States)

Author keywords

Anti endoglin monoclonal antibodies; Betaglycan; Carcinogenesis; Childhood brain tumors; Endogenous mediators of angiogenesis; Endoglin (CD105); Endothelial cell markers; Glial neoplasms; Growth factors pidermal growth factor (EGF); H ras; Mammalian neoplasm related angiogenesis; Medulloblastoma (MED) primitive neuroectodermal tumor (PNET); Oncogenes; p53; TGF type I and type II receptors; Transforming growth factors (TGFs); Vascular endothelial growth factor permeability factor (VEGF PF)

Indexed keywords

ANGIOGENESIS INHIBITOR; ENDOGLIN; MONOCLONAL ANTIBODY;

ANGIOGENESIS; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ASTROCYTOMA; BRAIN TUMOR; CHILDHOOD CANCER; ENDOTHELIUM CELL; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; MEDULLOBLASTOMA; PRIORITY JOURNAL; REVIEW; TUMOR VASCULARIZATION;

EID: 0031829703     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (258)

1. Packer RJ: Brain tumors in children. Curr Opin Pediatr 8: 549-557, 1996.
2. Vernon-Levett P, Geller M: Posterior fossa tumors in children: a case study. AACN Clin Issues 8: 214-226, 1997.
3. Allen JC, Siffert J: Contemporary issues in the management of childhood brain tumors. Curr Opin Neurol 10: 137-141, 1997.
4. Zeltzer PM: Chemotherapy for medulloblastoma: A review of treatment in recurrent and de novo tumors. In: Medulloblastomas in Children: New Concepts in Tumor Biology, Diagnosis and Treatment. (Zeltzer PM, Pochedly C, eds) New York, Praeger, 1986, pp 182-199.
5. Tomita T, McLone DG, Yasue M: Cerebral primitive neuroectodermal tumors in childhood. J Neuro-Oncol 6: 233-243, 1988.
6. Ilveskoski I, Pihko H, Sankila R, Lanning M, Perkkio M, Aarimaa T, Makipernaa A, Saarinen UM: Improving outcome of malignant brain tumours in very young children: a population-based study in Finland during 1975-93. Acta Paediatrica 86: 724-729, 1997.
7. Kun LE: Brain tumors. Challenges and directions. Pediatric Clin North Am 44: 907-917, 1997.
8. Kuttesch JF Jr: Advances and controversies in the management of childhood brain tumors. Current Opinion Oncol 9: 235-240, 1997.
9. Hartsell WF, Gajjar A, Heideman RL, Langston JA, Sanford RA, Walter A, Jones D, Chen G, Kun LE: Patterns of failure in children with medulloblastoma: effects of preirradiation chemotherapy. Int J Radiation Oncol Biol Phys 39: 15-24, 1997.
10. Bailey P, Cushing H: Medulloblastoma cerebelli, a common type of midcerebellar glioma of childhood. Arch Neurol Psychiatry 14: 192-224, 1925.
11. Schaper A: Einige kritische Bemerkungen zu Lugaro's Aufsatz: "Ueber die Histogenese der Korner der Kleinhirnrinde". Anat Anz 10: 422-426, 1895.
12. Camins MB, Cravieta HM, Epstein F, Ransohoff J: Medulloblastoma: An ultrastructural study - evidence for astrocytic and neuronal differentiation. Neurosurgery 6: 398-411, 1980.
13. Packer RJ, Sutton LN, Rorke LB, Littman PA, Sposto R, Rosenstock JG, Bruce DA, Schut L: Prognostic importance of cellular differentiation in medulloblastoma of childhood. J Neurosurg 61: 296-301, 1984.
14. Caputy AJ, McCullough DC, Manz HJ, Patterson K, Hammock MK: A review of the factors influencing the prognosis of medulloblastoma. The importance of cell differentiation. J Neurosurg 66: 80-87, 1987.
15. Hart MN, Earle KM: Primitive neuroectodermal tumors of the brain in children. Cancer 32: 890-897, 1973.
16. Rorke L: The cerebellar medulloblastoma and its relationship to primitive neuroectodermal tumors. J Neuropathol Exp Neurol 42: 1-15, 1983.
17. Rorke LB: Origin and histogenesis of medulloblastoma. In: Medulloblastomas in Children: New Concepts in Tumor Biology, Diagnosis and Treatment. (Zeltzer PM, Pochedly C, eds) New York, Praeger, 1986, pp 14-21.
18. Rorke LB, Gilles FR, Davis RL, Becker LE: Revision of the World Health Organization Classification of Brain Tumors for Childhood Brain Tumors. Cancer 56(Suppl): 1869-1886, 1985.
19. Rubinstein LJ: A commentary on the proposed revision of the World Health Organization classification of brain tumors for childhood brain tumors. Cancer 56(Suppl): 1887-1888, 1985
20. Bodian M, Lawson D: The intracranial neoplastic diseases of childhood: A description of their natural history based on a clinicopathological study of 129 cases. Br J Surg 40: 368-392, 1953.
21. Matakas F, Cervos-Navarro J, Gullotia F: The ultrastructure of medulloblastomas. Acta Neuropathol 16: 271-284, 1970.
22. Rubinstein LJ: Embryonal central neuroepithelial tumors and their differentiating potential: A cytogenetic view of a complex neurooncological problem. J Neurosurg 62: 795-805, 1985.
23. Rubinstein LJ, Herman MM, van der Berg SR: Differentiation and anaplasia in central neuroepithelial tumors. Prog Exp Tumor Res 27: 32-48, 1984.
24. Rubinstein LJ: The cerebellar medulloblastoma: Its origin, differentiation, morphological variants, and biological behavior. In: Tumors of The Brain and Skull. Part III. (Vincken PJ, Bruyn GW, eds) New York, Elsevier, 1975, pp 167-194.
25. Trojanowski JQ, Lee VM-Y, Schlaepfer WW: An immunohistochemical study of human central and peripheral nervous system tumors, using monoclonal antibodies against neurofilaments and glial filaments. Hum Pathol 15: 248-257, 1984.
26. Roessmann U, Velasco ME, Gambetti P, Autilio-Gambetti L: Neuronal and astrocytic differentiation in human neuroepithelial neoplasms. J Neuropath Exp Neurol 42: 113-121, 1983.
27. Gullotta F, Kersting G: The ultrastructure of medulloblastoma in tissue culture. Virchows Arch (Pathol Anat) 356: 111-118, 1972.
28. Palmer JO, Kasselberg AG, Netsky MG: Differentiation of medulloblastoma: Studies including immunohistochemical localization of glial fibrillary acidic protein. J Neurosurg 55: 161-169, 1981.
29. Roy S: An ultrastructural study of medulloblastoma. Neurol India 25: 226-229, 1977.
30. Dickson DW, Hart MN, Menezes A, Cancilla PA: Medulloblastoma with glial and rhabdomyoblastic differentiation. J Neuropathol Exp Neurol 42: 639-647, 1983.
31. Kemohan JW, Mabon RF, Svien YU, Adson AW: A simplified classification of gliomas. Proc Staff Meet Mayo Clin 24: 71-75, 1949.
32. Ringertz J: Grading of Gliomas. Acta Pathol Microbiol Scand 27: 51-64, 1950.
33. Kemohan JW, Sayre GP: Tumors of Central Nervous System. Fascicle 35, Atlas of Tumor Pathology. Armed Forces Institute of Pathology, Washington, pp 17-129, 1952.
34. Zulch KJ: Histological typing of tumors of central nervous system. International histological classification of tumours. World Health Organisation, Geneva, 21: 1-56, 1979.
35. Nelson JS, Tuskada Y, Schoenfeld D, Fulling K, Lamarche J, Peress N: Necrosis as a prognostic criteria in malignant supratentorial astrocytic gliomas. Cancer 52: 550-554, 1983.
36. Burger PC, Vogel FS, Green SB, Strike AT: Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications. Cancer 56: 1106-1111, 1985.
37. DeArmond SJ: In situ cell kinetic studies on human neuroectodermal tumors with bromodeoxyuridine labeling. J Neurosurg 64: 453-59, 1986.
38. Shapiro JR: Biology of gliomas. Heterogenity, oncogenes, growth factors. Semin Oncol 133: 4-15, 1986.
39. Hoshino T, Rodriguez LA, Cho KC, Lee KS, Wilson CB, Edwards MSB, Levin VA, Davis RL: Prognostic implications of the proliferative potential of low grade astrocytomas. J Neurosurg 69: 839-1342, 1988.
40. Hoshino T, Prados NI, Wdson CB, Cho KC, Lee KS, Davis RL: Prognostic implications of low bromodeoxyuridine labeling index of human gliomas. J Neurosurg 71: 335-341, 1989.
41. Burger PC, Kleihues P: Cytologic composition of the untreated glioblastoma with implications for evaluation of needle biopsies. Cancer 63: 2014-2023, 1989.
42. Russel DS, Rubinstein LJ: Tumors of neuroepithelial origin In: Pathology of Tumours of the Nervous System. 5th Edition, Edward Arnold, London, 1989, pp 83-350.
43. Bodey B, Zeltzer PM, Saldivar V, Kemshead J: Immuno-phenotyping of childhood astrocytomas with a library of monoclonal antibodies. Int J Cancer 45: 1079-1087, 1990.
44. Weller RO: Tumours of the nervous system. In: Systemic Pathology, 3rd Edition. Volume IV. (Symmers SC, ed) Churchill Livingston, Edinburgh, 1990, pp 427-503.
45. Schmitt BP, Oberwittler C, Schad LR: Computer aided classification of malignancy in astrocytomas: I. The value of nuclear parameters obtained by automated black and white image analysis. Analyt Cell Pathol 4: 397-407, 1992.
46. Schmitt HP, Oberwittler C: Computer aided classification of malignancy in astrocytomas II. The value of categorically evaluating histologic and nonhistologic features for a numerical classifier. Analyt Cell Pathol 4: 409-419, 1992.
47. Kleihues P, Burger PC, Scheithauer BW: Histological typing of tumors of the central nervous system. International histological classification of tumours. 2nd Edition, World Health Organisation, Springer Verlag, Berlin, 1993.
48. Dinda AK, Kharbanda K, Sarkar C, Roy S, Mathur M, Banedi AK: In vivo proliferative potential of primary human brain tumors. Its correlation with histological classification and morphological features. I. Gliomas Pathology 25: 4-9, 1993.
49. Dinda AK, Kharbanda K, Sarkar C, Roy S, Mathur M, Banedi AK: In-vivo proliferative potential of primary human brain tumors. Its correlation with histological classification and morphological features. II. Nonglial Tumors. Pathology 25: 10-14, 1993.
50. Burger PC, Scheithauer BW: Tumors of the central nervous system. Armed Forces Institute of Pathology, Washington, 1994.
51. Sharma S, Karak AK, Sarkar C, Gomathy G, Bannedi AK, Schmitt HP: A grading study of gliomas using histologic morphometry and malignancy classification. J Neuro-Oncol 27: 75-85, 1996.
52. Bodey B, Gröger AM, Bodey B Jr, Siegel SE, Kaiser HE: Immunocytochemical detection of p53 protein expression in various childhood astrocytoma subtypes: Significance in tumor progression. Anticancer Res 17: 1187-1194, 1997.
53. Louis DN: A molecular genetic model of astrocytoma histopathology. Brain Pathol 7: 755-764, 1997.
54. Gastl G, Hermann T, Steurer M, Zmija J, Gunsilius E, Unger C, Kraft A: Angiogenesis as a target for tumor treatment. Oncology 54: 177-184, 1997.
55. Folkman J: Angiogenesis in cancer, vascular, rheumatoid, and other disease. Nature Med 1: 27-31, 1995.
56. Cockerill GW, Gamble JR, Vadas MA: Angiogenesis: models and modulators. Int Rev Cytol 159: 113-160, 1995.
57. Risau W: Differentiation of endothelium. FASEB J 9: 926-933, 1995.
58. Risau W, Flamme I: Vasculogenesis. Annu Rev Cell Dev Biol 11: 73-91, 1995.
59. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364, 1996.
60. Bicknell R, Harris AL: Mechanisms and therapeutic implications of angiogenesis. Curr Opin Oncol 8: 60-65, 1996.
61. Folkman J: Addressing tumor blood vessels. Nature Biotechnol 15: 510, 1997.
62. Folkman J: Angiogenesis and angiogenesis inhibition: an overview. EXS 79: 1-8, 1997.
63. Pietsch T, Valter MM, Wolf HK, von Deimling A, Su Huang H-J, Cavenee WK, Wiestler OD: Expression and distribution of vascular endothelial growth factor protein in human brain tumors. Acta Neuropathol 93: 109-117, 1997.
64. Price JT, Bonovich MT, Kohn EC: The biochemistry of cancer dissemination. Crit Rev Biochem Mol Biol 32: 175-253, 1997.
65. Salven P, Heikkila MD, Anttonen A, Kajanti M, Joensuu H: Vascular endothelial growth factor in squamous cell head and neck carcinoma: expression and prognostic significance. Modern Pathol 10: 1128-1133, 1997.
66. Folkman J, Klagsbrun M: Angiogenic factors. Science 235: 442-447, 1987.
67. Keck PJ, Hauser SD, Krivi G, Saazo K, Warren T, Feder J, Connolly DT: Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246: 1309-1312, 1989.
68. Plate KH, Breier G, Weich HA, Risau W: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359: 845-848, 1992
69. Goldman CK, Kim J, Wong WL, King V, Brock T, Gillespie GY: Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 4: 121-133, 1993.
70. Meir EG van, Polverini PJ, Chazin VR, Su Huang H-J, de Tribolet N, Cavenee WK: Release of an inhibitor of angiogenesis upon induction of wild-type p53 expression in glioblastoma cells. Nat Genet 8: 171-176, 1994.
71. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A: Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367: 576-579, 1994.
72. Czubayko F, Smith RV, Chung HC, Wellstein A: Tumor growth and angiogenesis induced by a secreted binding protein for fibroblast growth factors. J Biol Chem 269: 28243-28248, 1994.
73. Risau W: What, if anything, is an angiogenic factor? Cancer Metast Rev 15: 149-151, 1996.
74. Czubayko F, Liadet-Coopman EDE, Aigner A, Tuveson AT, Berchem GJ, Wellstein A: A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nature Med 3: 1137-1140, 1997.
75. Rak J, Kerbel RS: bFGF and tumor angiogenesis-back in the limelight? Nature Med 3: 1083-1084, 1997.
76. Dameron KM, Volpert OV, Taisnky MA, Bouck N: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265: 1582-1584, 1994.
77. Bertin N, Clezardin P, Kubiak R, Frappart L: Thrombospondin-1 and -2 messenger RNA expression in normal, benign, and neoplastic human breast tissues: correlation with prognostic factors, tumor angiogenesis, and fibroblastic desmoplasia. Cancer Res 57: 396-399, 1997.
78. Choudhuri R, Zhang H-T, Donnini S, Ziehe M, Bicknell R: An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. Cancer Res 57: 1814-1819, 1997.
79. Koochekpour S, Jeffers M, Rulong S, Taylor G, Klineberg E, Hudson EA, Resau JH, Vande Woude GF: Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res 57: 5391-5398, 1997.
80. O'Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL: Two mechanisms of basic fibroblast growth factor-induced angiogenesis in bladder cancer. Cancer Res 57: 136-140, 1997.
81. Holmgren L, O'Reilly MS, Folkman J: Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med 1: 149-153, 1995.
82. Samoto K, Ikezaki K, Ono M, Shono T, Kohno K, Kuwano M, Fukui M: Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res 55: 1189-1193, 1995.
83. Berkman RA, Merrill MJ, Reinhold WC, Monacci WT, Saxena A, Clark WC, Robertson JT, Ali IU, Oldfield EH: Expression of the vascular permeability factor /vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest 91: 153-159, 1993.
84. Morii K, Tanaka R, Washiyama K, Kumanishi T, Kuwano R: Expression of vascular endothelial growth factor in capillary hemangioblastoma. Biochem Biophys Res Commun 194: 749-755, 1993.
85. Wizigmann-Voos S, Breier G, Risau W, Plate KH: Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. Cancer Res 55: 1358-1364, 1995.
86. Takano S, Yoshii Y, Kondo S, Suzuki H, Maruno T, Shirai S, Nose T: Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res 56: 2185-2190, 1996.
87. Risau W: Embryonic angiogenesis factors. Pharmacol Ther 51: 371-376, 1991.
88. Breier G, Albrecht U, Sterrer S, Risau W: Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development 114: 521-532, 1992.
89. Risau W: Molecular biology of blood-brain barrier ontogenesis and function. Acta Neurochir (Wien) [Suppl] 60: 109-112, 1994.
90. Zagzag D: Angiogenic growth factors in neural embryogenesis and neoplasia. Am J Pathol 146: 293-309, 1995.
91. Plate KH, Breier G, Weich HA, Mennel HD, Risau W: Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 59: 520-529, 1994.
92. Bouck N: Angiogenesis: a mechanism by which oncogenes and tumor suppressor genes regulate tumorigenesis. Cancer Treat Res 63: 359-371, 1992.
93. Shim JW, Koh YC, Ahn HK, Park YE, Hwang DY, Chi JG: Expression of bFGF and VEGF in brain astrocytoma. J Korean Med Sci 11: 149-157, 1996.
94. Melnyk O, Shuman MA, Kim KJ: Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth. Cancer Res 56: 921 -924, 1996.
95. Barleon B, Totzke F, Herzog C, Blanke S, Kremmer E, Siemeister G, Marme D, Martiny-Baron G: Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1. J Biol Chem 272: 10382-10388, 1997.
96. Stoker M: Effect of scatter factor on motility of epithelial cells and fibroblasts. J Cell Physiol 139: 565-569, 1989.
97. Stoker M, Gherardi E: Scatter factor and other regulators of cell mobility. Br Med Bull 45: 481-491, 1989.
98. Stoker M, Gherardi E: Regulation of cell movement: the motogenic cytokines. Biochim Biophys Acta 1072: 81-102, 1991.
99. Stan AC, Walter GF, Welte K, Pietsch T: Immunolocalization of granulocyte-colony- stimulating factor in human glial and primitive neuroectodermal tumors. Int J Cancer 57: 306-312, 1994.
100. van den Hoff A: Stromal involvement in malignant growth. Adv Cancer Res 50: 159-196, 1988.
101. Risau W, Lemmon V: Changes in the vascular extracellular matrix during embryonic vasculogenesis and angiogenesis. Dev Biol 125: 441-450, 1988.
102. Neri D, Carnemolla B, Nissim A, Leprini A, Querze G, Balza E, Pini A, Tarli L, Halin C, Neri P, Zardi L, Winter G: Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nature Biotechnol 15: 1271-1275, 1997.
103. Shweiki D, Itin A, Softer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 559: 843-845, 1992.
104. Lehnert SA, Akhurst RJ: Embryonic expression pattern of TGF-beta type I RNA suggests both paracrine and autocrine mechanisms of action. Development 104: 263-273, 1988.
105. Fox FE, Ford HC, Douglas R, Cherian S, Nowell PC: Evidence that TGF-beta can inhibit human T-lymphocyte proliferation through paracrine and autocrine mechanisms. Cellular Immunol 150: 45-58, 1993.
106. de Larco JE, Todaro GJ: Growth factors from murine sarcoma virus-transformed cells. Proc Natl Acad Sci USA 75: 4001-4005, 1978.
107. Todaro GJ, Fryling C, de Larco JE: Transforming growth factors produced by certain human tumor cells: polypeptides that interact with epidermal growth factor receptors. Proc Natl Acad Sci USA 77: 5258-5262, 1980.
108. Goustin AS, Leof EB, Shipley GD, Moses HL: Growth factors and cancer. Cancer Res 46: 1015-1029, 1986.
109. Massague J: Epidermal growth factor-like transforming growth factor. I. Isolation, chemical characterization, and potentiation by other transforming factors from feline sarcoma virus-transformed rat cells. J Biol Chem 258: 13606-13613, 1983.
110. Cheifetz S, Weatherbee JA, Tsang ML-S, Anderson JK, Mole JE, Lucas R, Massague J: The transforming growth factor-beta system, a complex pattern of cross-reactive ligands and receptors. Cell 48: 409-415, 1987.
111. Van Obberghen-Schilling E, Roche NS, Flanders KC, Sporn MB, Roberts AB: Transforming growth factor beta 1 positively regulates its own expression in normal and transformed cells. J Biol Chem 263: 7741-7746, 1988.
112. Barnard JA, Beauchamp RD, Coffey RJ, Moses HL: Regulation of intestinal epithelial cell growth by transforming growth factor type beta. Proc Natl Acad Sci USA 86: 1578-1582, 1989.
113. Bascom CC, Wolfshohl JR, Coffey RJ, Madisen L, Webb NR, Purchio AR, Derynck R, Moses HL: Complex regulation of transforming growth factor beta1, beta2, and beta3 mRNA expression in mouse fibroblasts and keratinocytes by transforming growth factors beta1 and beta2. Mol Cell Biol 9: 5508-5515, 1989.
114. Massague J, Andres J, Attisano L, Cheifetz S, Lopez-Casillas F, Ohtsuki M, Wrana JL: TGF-beta receptors. Mol Repr Dev 32: 99-104, 1992.
115. Massague J, Cheifetz S, Laiho M, Ralph DA, Weis FM, Zentella A: Transforming growth factor-beta. Cancer Surv 12: 81-103, 1992.
116. Barnard JA, Lyons RM, Moses HL: The cell biology of transforming growth factor beta. Biochim Biophys Acta 1032: 79-87, 1990.
117. Attisano L, Wrana JL: Signal transduction by members of the transforming growth factor- beta superfamily. Cytokine Growth Factor Rev 7: 327-339, 1996.
118. ten Dijke P, Franzen P, Yamashita H, Ichijo H, Heldin CH, Miyazono K: Serine/threonine kinase receptors. Prog Growth Factor Res 5: 55-72, 1994.
119. Derynck R, Jarrett JA, Chen EY, Eaton DH, Bell JR, Assoian RK, Roberts AB, Sporn MB, Goeddel DV: Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature 316: 701-705, 1985.
120. Hanks SK, Armor R, Baldwin JH, Maldonado F, Spiess J, Holley RW: Amino acid sequence of the BSC-I cell growth inhibitor (polyergin) deduced from the nucleotide sequence of the cDNA. Proc Natl Acad Sci USA 85: 79-82, 1988.
121. Madisen L, Webb NR, Rose TM, Marquardt H, Ikeda T, Twardzik D, Seyedin S, Purchio AF: Transforming growth factor-beta2: cDNA cloning and sequence analysis. DNA 7: 1-8, 1988.
122. ten Dijke P, Hansen P, Iwata KK, Peiler C, Foulkes JG: Identification of another member of the transforming growth factor type beta gene family. Proc Natl Acad Sci USA 85: 4715-4719, 1988.
123. Roberts AB, Sporn MB: The transforming growth factors beta. In: Handbook of experimental pharmacology, Vol 95/I: Peptide growth factors and their receptors. (Sporn MB, Roberts AB, eds) Springer Verlag, Heidelberg, pp 419-472, 1990.
124. Miyazono K: Transforming growth factor-beta and its receptors. Nippon Yakurigaku Zasshi 107: 133-140, 1996.
125. Miyazono K: TGF-beta receptors and signal transduction. Int J Hematol 65: 97-104, 1997.
126. Roberts AB, Frolik CA, Anzano MA, Sporn MB: Transforming growth factors from neoplastic and nonneoplastic tissues. Fed Proc 22: 2621-2626, 1983.
127. Frolik CA, Dart LL, Meyers CA, Smith DM, Sporn MB: Purification and initial characterization of a type beta transforming growth factor from human placenta. Proc Natl Acad Sci USA 80: 3676-3680, 1983.
128. Assoian RK, Komoriya A, Meyers CA, Miller DM, Sporn MB: Transforming growth factor-beta in human platelets: identification of a major storage site, purification, and characterization. J Biol Chem 258: 7155-7160, 1983.
129. Fujii D, Brissenden JE, Derynck R, Francke U: Transforming growth factor beta gene maps to human chromosome 19 long arm and to mouse chromosome 7. Somatic Cell Mol Genet 12: 281-288, 1986.
130. Barton DE, Foellmer BE, Du J, Tamm J, Derynck R, Francke U: Chromosomal mapping of genes for transforming growth factors beta 2 and beta 3 in man and mouse: dispersion of TGF-beta gene family. Oneogene Res 3: 323-331, 1988.
131. Wilcox JN, Derynck R: Developmental expression of Transforming Growth Factors alpha and beta in mouse fetus. Mol Cell Biology 8: 3415-3422, 1988.
132. Keller JR, Mcniece IK, Sill KT, Ellingsworth LR, Quesenberry PJ, Sing GK, Ruscetti FW: Transforming growth factor beta directly regulates primitive murine hematopoietie cell proliferation. Blood 75: 596-602, 1990.
133. Sharples K, Plowman GD, Rose TM, Twardzik DR, Purchio AF: Cloning and sequence analysis of simian transforming growth factor-beta cDNA. DNA 6: 239-244, 1987.
134. Derynck R, Rhee L: Sequence of the porcine transforming growth factor-beta precursor. Nucleic Acids Res 15: 3187, 1987.
135. Van Obberghen-Schilling E, Kondaiah P, Ludwig RL, Sporn MB, Baker CC: Complementary deoxyribonucleic acid cloning of bovine transforming growth factor-beta 1. Mol Endocrinol 1: 693-698, 1987.
136. Fontana A, Hengartner H, de Tribolet N, Weber E: Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects. J Immunol 132: 1837-1844, 1984.
137. Wrann M, Bodmer S, de Martin R, Siepl C, Hofer-Warbinek R, Frei K, Hofer E, Fontana A: T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor beta. EMBO J 6: 1633-1636, 1987.
138. Siepl C, Bodmer S, Frei K, MacDonald HR, De Martin R, Hofer E, Fontana A: The glioblastoma-derived T cell suppressor factor/transforming growth factor-beta 2 inhibits T cell growth without affecting the interaction of interleukin 2 with its receptor. Eur J Immunol 18: 593-600, 1988.
139. Frolik CA, Wakefield LM, Smith DM, Sporn MB: Characterization of a membrane receptor for transforming growth factor-beta in normal rat kidney fibroblasts. J Biol Chem 259: 10995-11000, 1984.
140. Tucker RF, Branum EL, Shipley GD, Ryan RJ, Moses HL: Specific binding to cultured cells of 125I-labeled type beta transforming growth factor from human platelets. Proc Natl Acad Sci USA 81: 6757-6761, 1984.
141. Massague J: Type beta transforming growth factor from feline sarcoma virus-transformed cells. Isolation and biological properties. J Biol Chem 259: 9756-9761, 1984.
142. Segarini PR: TGF-beta receptors. Clinical applications of TGF-beta. Wiley, Chichester (CIBA Foundation Symposium # 157), 1991; pp. 29-50.
143. Massague J, Like B: Cellular receptors for type beta transforming growth factor. Ligand binding and affinity labeling in human and rodent cell lines. J Biol Chem 260: 2636-2645, 1985.
144. Wrana JL, Carcamo J, Attisano L, Cheifetz S, Zentella A, Lopez-Casillas F, Massague J: The type II TGF-beta receptor signals diverse responses in cooperation with the type I receptor. Cold Spring Harb Symp Quant Biol 57: 81-86, 1992.
145. Laiho M, Weis FMB, Boyd FT, Ignotz RA, Massague J: Responsiveness of transforming growth factor beta (TGF-beta) restored by genetic complementation between cells defective in TGF-beta receptors I and II. J Biol Chem 266: 9108-9112, 1992.
146. Lin HY, Wang X-F, Ng-Eaton E, Weinberg RA, Lodish HF: Expression cloning of the TGF-beta type II receptor, a functional transmembrane serine/threonine kinase. Cell 68: 775-785, 1992.
147. Bodey B, Bodey B Jr, Hall FL: Expression of Transforming Growth Factor-beta type II receptors in the cells of the human thymic microenvironment during ontogenesis. In: Molecular Biology of Hematopoiesis. Volume V. (Abraham NG, Asano S, Brittinger G, Maestroni GJM, Shadduck R, eds) New York, Plenum Press, 1996. Chapter 78, pp. 645-658.
148. Burrows FJ, Derbyshire EJ, Tazzari PL, Amlot P, Gazdzar AF, King SW, Letarte M, Vitetta ES, Thorpe PE: Up-regulation of endoglin on vascular endothelial cells in human solid tumors: Implications for diagnosis and therapy. Clin Cancer Res 1: 1623-1634, 1995.
149. Kumar P, Wang JM, Bernaheu C: CD105 and angiogenesis. J Pathol 178: 363-366, 1996.
150. Fernandez-Ruiz E, St-Jacques S, Bellon T, Letarte M, Bernabeu C: Assignment of the human endoglin gene (END) to 9q34 ->qter. Cytogenet Cell Genet 64: 204-207, 1993.
151. Wang JM, Kumar S, van Agthoven A, Kumar P, Pye D, Hunter RD: Irradiation induces up-regulation of E9 protein (CD105) in human vascular endothelial cells. Int J Cancer 62: 791-796, 1995.
152. Yamada N, Kato M, Yamashita H, Nister M, Miyazono K, Heldin CH, Funa K: Enhanced expression of transforming growth factor-beta and its type-I and type-II receptors in human glioblastoma. Int J Cancer 62: 386-392, 1995.
153. Henriksen R, Gobl A, Wilander E, Oberg K, Miyazono K, Funa K: Expression and prognostic significance of TGF-beta isotypes, latent TGF-beta 1 binding protein, TGF- beta type I and type II receptors, and endoglin in normal ovary and ovarian neoplasms. Lab Invest 73: 213-220, 1995.
154. Szekanecz Z, Haines GK, Harlow LA, Shah MR, Fong TW, Fu R, Lin SJ, Rayan G, Koch AE: Increased synovial expression of transforming growth factor (TGF)-beta receptor endoglin and TGF-beta 1 in rheumatoid arthritis: possible interactions in the pathogenesis of the disease. Clin Immunol Immunopathol 76: 187-194, 1995.
155. Zhang H, Shaw AR, Mak A, Letarte M: Endoglin is a component of the transforming growth factor (TGF)-beta receptor complex of human pre-B leukemic cells. J Immunol 156: 564-573, 1996.
156. Griffioen AW, Damen CA, Blijham GH, Groenewegen G: Endoglin/CD 105 may not be an optimal tumor endothelial treatment target. Breast Cancer Res Treat 39: 239-242, 1996.
157. Shovlin CL, Scott J: Inherited diseases of the vasculature. Annu Rev Physiol 58: 483-507, 1996.
158. Pichuantes S, Vera S, Bourdeau A, Pece N, Kumar S, Wayner EA, Letarte M: Mapping epitopes to distinct regions of the extracellular domain of endoglin using bacterially expressed recombinant fragments. Tissue Antigens 50: 265-276, 1997.
159. Gougos A, Letarte M: Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. J Biol Chem 265: 8361-8364, 1990.
160. Lopez-Casillas F, Cheifetz S, Doody J, Andres JL, Lane WS, Massague J: Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-beta receptor system. Cell 67: 785-795, 1991.
161. Altomonte M, Montagner R, Fonsatti E, Colizzi F, Cattarossi I, Brasoveanu LI, Nicotra MR, Cattelan A, Natali PG, Maio M: Expression and structural features of endoglin (CD105), a transforming growth factor beta1 and beta3 binding protein, in human melanoma. Br J Cancer 74: 1586-1591, 1996.
162. Cheifetz S, Bellon T, Cales C, Vera S, Bernabeu C, Massague J, Letarte M: Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem 267: 19027-19030, 1992.
163. Lastres P, Bellon T, Cabanas C, Sanchez-Madrid F, Acevedo A, Gougos A, Letarte M, Bernabeu C: Regulated expression on human macrophages of endoglin, an Arg-Gly-Asp- containing surface antigen. Eur J Immunol 22: 393-397, 1992.
164. Westphal JR, Willems HW, Schalkwijk CJ, Ruiter DJ, de Waal RM: A new 180-kDa dermal endothelial cell activation antigen: in vitro and in situ characteristics. J Invest Dermatol 100: 27-34, 1993.
165. Westphal JR,. Willems HW, Schalkwijk CJ, Ruiter DJ, De Waal RM: Characteristics and possible function of endoglin, a TGF-beta binding protein. Behring Inst Mitt 92: 15-22, 1993.
166. Lopez-Casillas F, Payne HM, Andres JL, Massague J: Betaglycan can act as a dual modulator of TGF-beta access to signaling receptors: mapping of ligand binding and GAG attachment sites. J Cell Biol 124: 557-568, 1994.
167. Ge AZ, Butcher EC: Cloning and expression of a cDNA encoding mouse endoglin, an endothelial cell TGF-heta ligand. Gene 138: 201-206, 1994.
168. St-Jacques S, Cymerman U, Pece N, Letarte M: Molecular characterization and in situ localization of murine endoglin reveal that it is a transforming growth factor-beta binding protein of endothelial and stromal cells. Endocrinology 134: 2645-2657, 1994.
169. Yamashita H, Ichijo H, Grimsby S, Moren A, ten Dijke P, Miyazono K: Endoglin forms a heteromeric complex with the signaling receptors for transforming growth factor-beta. J Biol Chem 269: 1995-2001, 1994.
170. Lastres P, Martin-Perez J, Langa C, Bernabeu C: Phosphorylation of the human-transforming-growth-factor-beta-binding protein endoglin. Biochem J 301: 765-768, 1994.
171. Cheifetz S, Bellon T, Cales C, Vera S, Bernabeu C, Massague J, Letarte M: Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem 267: 19027-19030, 1992.
172. Haruta Y, Seon BK: Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6. Proc Natl Acad Sci USA 83: 7898-7902, 1986.
173. Gougos A, Letarte M: Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line. J Immunol 141: 1925-1933, 1988.
174. Gougos A, St Jacques S, Greaves A, O'Connell PJ, d'Apice AJ, Buhring HJ, Bernabeu C, van Mourik JA, Letarte M: Identification of distinct epitopes of endoglin, an RGD- containing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblasts. Int Immunol 4: 83-92, 1992.
175. Buhring HT, Muller CA, Letarte M, Gougos A, Saalmuller A, van Agthoven AJ, Busch FW: Endoglin is expressed on a subpopulation of immature erythroid cells of normal human bone marrow. Leukemia 5: 841-847, 1991.
176. Bellon T, Corbi A, Lastres P, Cales C, Cebrian M, Vera S, Cheifetz S, Massague J, Letarte M, Bernabeu C: Identification and expression of two forms of the human transforming growth factor-beta-binding protein endoglin with distinct cytoplasmic regions. Eur J Immunol 23: 2340-2345, 1993.
177. Lastres P, Letamendia A, Zhang H, Rius C, Almendro N, Raab U, Lopez LA, Langa C, Fabra A, Letarte M, Bernabeu C: Endoglin modulates cellular responses to TGF-beta 1. J Cell Biol 133: 1109-1121, 1996.
178. O'Connell PJ, McKenzie A, Fisicaro N, Rockman SP, Pearse MJ, d'Apice AJ: Endoglin: a 180-kD endothelial cell and macrophage restricted differentiation molecule. Clin Exp Immunol 90: 154-159, 1992.
179. Farmilo AJ, Stead RH: Fixation in immunocytochemistry. In: Handbook Immunochemical Staining Methods. (Naish SJ, ed) DAKO Corporation, 1989, pp24-29.
180. Weidner N: Intratumoral microvessel density as a prognostic factor in cancer. Am J Pathol 147: 9-19, 1995.
181. Martin L, Holcombe C, Green B, Leinster SJ, Winstanley J: Is a histological section representative of whole tumour vascularity in breast cancer? Brit J Cancer 76: 40-43, 1997.
182. Wang JM, Kumar S, Pye D, van Agthoven AJ, Krupinski J, Hunter RD: A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues. Int J Cancer 54: 363-370, 1993.
183. Bodey B, Bodey B Jr, Siegel SE, Luck JV, Kaiser HE: Immunophenotypic characterization of human primary and metastatic melanoma infiltrating autologous immunological effector cells. Anticancer Res 16: 3439-3446, 1996.
184. Bodey B, Bodey B Jr, Gröger AM, Siegel SE, Kaiser HE: Clinical and prognostic significance of Ki-67 and proliferating cell nuclear antigen expression in childhood primitive neuroectodermal brain tumors. Anticancer Res 17: 189-196, 1997.
185. Bodey B, Bodey B Jr, Gröger AM, Siegel SE, Kaiser HE: Nm23/nucleoside diphosphate (NDP) kinase expression in human malignant melanomas. Significance and implications in tumor biology. Anticancer Res 17: 505-512, 1997.
186. Bodey B, Gröger AM, Bodey B Jr, Siegel SE, Kaiser HE: Immunocytochemical detection of p53 protein overexpression in primary human osteosarcomas. Anticancer Res 17: 493-498, 1997.
187. Bodey B, Bodey B Jr, Gröger AM, Luck JV, Siegel SE, Taylor CR, Kaiser HE: Immunocytochemical detection of the p170 multidrug resistance (MDR) and the p53 tumor suppressor gene proteins in human breast cancer cells: Clinical and therapeutical significance. Anticancer Res 17: 1311-1318, 1997.
188. Bodey B, Bodey B Jr, Gröger AM, Luck JV, Siegel SE, Taylor CR, Kaiser HE: Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas. Anticancer Res 17: 1319-1330, 1997.
189. Battifora H: The multitumor (sausage) tissue block: novel method for immunohistochemical antibody testing. Lab Invest 55: 244-248, 1986.
190. Battifora H, Mehta P: The checkerboard tissue block. An improved multitissue control block. Lab Invest 63: 722-724, 1990.
191. Greene HSN: The transplantation of human brain tumors to the brain of laboratory animals. Cancer Res 13: 422-426, 1953.
192. Bennett HS, Luft JH, Hampton JL: Morphological classification of vertebrate blood capillaries. Amer J Physiol 196: 381-390, 1959.
193. Dobbing J: The blood-brain barrier. Physiol Rev 41: 130-188, 1961.
194. Donahue S, Pappas G: Fine structure of capillaries of cerebral cortex of rat at stages of development. Amer J Anat 108: 331-349, 1961.
195. Tschirgi R: Blood-brain barrier: Fact or fantasy? Fed Proc 21: 665-676, 1962.
196. Shimoda A: An electron microscopic study of the developing rat brain concerned with the morphological basis of the blood-brain barrier. Acta Path Jap 13: 95-105, 1963.
197. Fox JL: Developments of recent thoughts on intracranial pressure and the blood-brain barrier. J Neurosurg 21: 909-967, 1964.
198. Krigman MR, Manuelidis EE: Morphological and permeability changes in the cerebral parenchyma adjacent to heterologous intracerebral tumors. J Neuropath Exp Neurol 22: 368-373, 1965.
199. Manuelidis EE, Dolin R: Fine structural studies on the vascularization of heterologously transplanted tumors. Ann NY Acad Sci 159: 432445, 1969.
200. Roberts WG, Palade GE: Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res 57: 765-772, 1997.
201. Clark WC, Bressler J: Transforming growth factor-β-like activity in tumors of the central nervous system. J Neurosurg 68: 920-924, 1988.
202. Zagzag D, Brem S, Robert F: Neovascularization and tumor growth in the rabbit brain: a model for experimental studies of angiogenesis and the blood-brain barrier. Am J Pathol 131: 361-372, 1988.
203. Zagzag D, Miller DC, Sato Y, Rifkin DB, Burstein DE: Immunohistochemical localization of basic fibroblast growth factor in astrocytomas. Cancer Res 50: 7393-7398, 1990.
204. Mapstone TB: Expression of platelet-derived growth factor and transforming growth factor and their correlation with cellular morphology in glial tumors. J Neurosurg 75: 447-451, 1991.
205. Brem S, Tsanaclis AMC, Gately S, Gross JL, Herblin WF: Immunolocalization of basic fibroblast growth factor to the microvasculature of human brain tumors. Cancer 70: 2673-2680, 1992.
206. Takashashi JA, Fukumoto M, Igarashi K, Oda Y, Kikuchi H, Hatanaka M: Correlation of basic fibroblast growth factor expression levels with the degree of malignancy and vascularity in human gliomas. J Neurosurg 76: 792-798, 1992.
207. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362: 841-844, 1993.
208. Vitolo D, Paradiso P, Uccini S, Ruco LP, Baroni CD: Expression of adhesion molecules and extracellular matrix proteins in glioblastomas: relation to angiogenesis and spread. Histopathology 28: 521-528, 1996.
209. St-Jacques S, Forte M, Lye SJ, Letarte M: Localization of endoglin, a transforming growth factor-beta binding protein, and of CD44 and integrins in placenta during the first trimester of pregnancy. Biol Reprod 57: 405-413, 1994.
210. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G: Tumor angiogenesis: a new significant and independent prognostic indicator in early- stage breast carcinoma. J Natl Cancer Inst 84: 1875-1887, 1992.
211. Karaiossifidi H, Kouri E, Arvaniti H, Sfikas S, Vasilaros S: Tumor angiogenesis in node- negative breast cancer: relationship with relapse free survival. Anticancer Res 16: 4001-4002, 1996.
212. Cohen ME, Duffner PK: Brain tumors in children. New York, Raven Press, pp 103-121, 1984.
213. Rivera-Luna R, Rueda-Franco F, Lanche-Guevara MT, Martinez-Guerra G: Multidisciplinary treatment of medulloblastomas in childhood. Child's Nerv Syst 3: 228-231, 1987.
214. Berry MP, Jenkin RD, Keen CW, Nair BD, Simpson WJ: Radiation treatment for medulloblastoma: A 21-year review. J Neurosurg 55: 43-51, 1981.
215. Cohen BH, Packer RJ: Chemotherapy for medulloblastomas and primitive neuroectodermal tumors. J Neuro-Oncol 29: 55-68, 1996.
216. Dirks PB, Harris L, Hoffman HJ, Humphreys RP, Drake JM, Rutka JT: Supratentorial primitive neuroectodermal tumors in children. J Neuro-Oncol 29: 75-84, 1996.
217. Dunkel IJ, Finlay JL: High dose chemotherapy with autologous stem cell rescue for patients with medulloblastoma. J Neuro-Oncol 29: 69-74, 1996.
218. Epstein F, Constantini S: Practical decisions in the treatment of pediatric brain tumors. Ped Neurosurg 24: 24-34, 1996.
219. Jenkin D: The radiation treatment of medulloblastoma. J Neuro-Oncol 29: 45-54, 1996.
220. Ilveskoski I, Saarinen UM, Perkkio M, Salmi TT, Lanning M, Makipemaa A, Sankila R, Pihko H: Chemotherapy with the "8 in 1" protocol for malignant brain tumors in children: a population-based study in Finland. Ped Hemat Oncol 13: 69-80, 1996.
221. Pezzotta S, Cordero di Montezemolo L, Knerich R, Arrigoni M, Barbara A, Besenzon L, Brach del Prever A, Fidani P, Locatelli D, Loiacono G, Magrassi L, Perilongo G, Rigobello L, Urgesi A, Madon E: CNS-85 trial: a cooperative pediatric CNS tumor study - results of treatment of medulloblastoma patients. Childs Nerv System 12: 87-96, 1996.
222. Sutton LN, Phillips PC, Molloy PT: Surgical management of medulloblastoma. J Neuro- Oncol 29: 9-21, 1996.
223. Allen JC, Siffert J: Contemporary chemotherapy issues for children with brainstem gliomas. Ped Neurosurgery 24: 98-102, 1996.
224. Campbell JW, Pollack IF, Martinez AJ, Shultz B: High-grade astrocytomas in children: radiologically complete resection is associated with an excellent long-term prognosis. Neurosugery 38: 258-264, 1996.
225. Lashford LS, Campbell RH, Gattamaneni HR, Robinson K, Walker D, Bailey C: An intensive multiagent chemotherapy regimen for brain tumours occurring in very young children. Arch Dis Childhood 74: 219-223, 1996.
226. Rettig WJ, Garin-Chesa P, Healey JH, Su SL, Jaffe EA, Old LJ: Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc Natl Acad Sci USA 89: 10832-10836, 1992.
227. Carnemolla B, Balza E, Siri A, Zardi L, Nicotra MR, Bigotti A, Natali PG: A tumor- associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J Cell Biol 108: 1139-1148, 1989.
228. Castellani P, Viale G, Dorcaratto A, Nicolo G, Kazmarek J, Querze G, Zardi L: The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int J Cancer 59: 612-618, 1994.
229. Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med 285: 1182-1186, 1971.
230. Folkman J: Clinical applications of research on angiogenesis. N Engl J Med 333: 1757-1763, 1995.
231. Fidler IJ, Ellis LM: The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79: 185-188, 1994.
232. Gasparini G, Harris AL: Clinical importance of the determination of tumor angiogenesis in breast carcinoma: Much more than a new prognostic tool. J Clin Oncol 13: 765-782, 1995.
233. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ: Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57: 1829-1834, 1997.
234. Cheng SY, Huang HJ, Nagane M, Ji XD, Wang D, Shih CC, Arap W, Huang CM, Cavenee WK: Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci U.S.A. 93: 8502-8507, 1996.
235. Lowy DR, Willumsen BM: Function and regulation of ras. Annu Rev Biochem 62: 851-891, 1993.
236. Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ, Waterfield MD, Downward J: Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370: 527-532, 1994.
237. Carraway KL, Carraway CA: Signaling, mitogenesis and the cytoskeleton: where the action is. Bioessays 17: 171-175, 1995.
238. Hu Q, Klippel A, Muslin AJ, Fantl WJ, Williams LT: Ras-dependent induction of cellular responses by constitutively active phosphatidylinositol-3 kinase. Science 268: 100-102, 1995.
239. Hu Q, Milfray D, Williams LT: Binding of NCK to SOS and activation of ras-dependent gene expression. Mol Cell Biol 15: 1169-1174, 1995.
240. Arbiser JL, Moses MA, Fernandez CA, Ghiso N, Cao Y, Klauber N, Frank D, Brownlee M, Flynn E, Parangi S, Byers HR, Folkman J: Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci USA 94: 861-866, 1997.
241. Folkman J: Fighting cancer by attacking its blood supply. Sci Am 275: 150-154, 1996.
242. Folkman J: New perspectives in clinical oncology from angiogenesis research. Eur J Cancer 32A: 2534-2539, 1996.
243. D'Amato RJ, Loughman MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91: 4082-4085, 1994.
244. Takano S, Gately S, Neville ME, Herblin WF, Gross JL, Engelhard H, Perricone M, Eidsvoog K, Brem S: Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res 54: 2654-2660, 1994.
245. Takamiya Y, Brem H, Ojeifo J, Mineta T, Martuza RL: AGM-1470 inhibits the growth of human glioblastoma cells in vitro and in vivo. Neurosurgery 34: 869-875, 1994.
246. Bosse DC, Parker JT, Vogler WR, Ades EW: Selective inhibition of adhesion molecule expression by edelfosine (ET-18-OCH3) on human umbilical vein or microvascular endothelium. Pathobiology 63: 109-114, 1995.
247. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J: Inhibition of angiogenesis in vivo by interleukin-12. J Natl Cancer Inst 87: 581-586, 1995.
248. Konno H, Tanaka T, Kanai T, Maruyama K, Nakamura S, Baba S: Effieacy of an angiogenesis inhibitor, TNP-470, in xenotransplanted human colorectal cancer with high metastatic potential. Cancer 77: 1736-1740, 1996.
249. Maier JA, Delia D, Thorpe PE, Gasparini G: In vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 (TNP-470) and the anti-endoglin antibody TEC-11. Anticancer Drugs 8: 238-244, 1997.
250. Lannutti BJ, Gately ST, Quevedo ME, Soff GA, Paller AS: Human angiostatin inhibits murine hemangioendothelioma tumor growth in vivo. Cancer Res 57: 5277-5280, 1997.
251. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285, 1997.
252. Klauber N, Parangi S, Flynn E, Hamel, E, D'Amato RJ: Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 57: 81 -86, 1997.
253. Sim BKL, O'Reilly MS, Liang H, Fortier AH, He W, Madsen JW, Lapcevich R, Nacy CA: A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res 57: 1329-1334, 1997.
254. Meir EG van, Polverini PI, Chazin VR, Su Huang HJ, Tribolet N de, Cavenee WK: Release of an inhibitor of angiogenesis upon induction of wild-type p53 expression in glioblastoma cells. Nature Genet 8: 171-176, 1994.
255. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T, Kerbel RS: Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 55: 4575-4580, 1995.
256. Rak J, Filmus J, Finkenzeller G, Grugel S, Marme D, Kerbel RS: Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev 14: 263-277, 1995.
257. Plate KH: Gene therapy of malignant glioma via inhibition of tumor angiogenesis. Cancer Metast Rev 15: 237-240, 1996.
258. Kaiser HE: Comparative aspects of neoplastic invasion of the brain. J Neurooncol 18: 163-170, 1993.